AbbVie Inc. (ABBV)
| Previous close | 161.52 |
| Open | 159.59 |
| Bid | 162.03 x 1200 |
| Ask | 162.09 x 1000 |
| Day's range | 159.72 - 162.24 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,765,625 |
| Market cap | 286.429B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 48.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.84%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
AbbVie Reports First-Quarter 2024 Financial Results
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ®, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT®, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of th
- PR Newswire
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO
